GC
MRTX

Guggenheim Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Guggenheim Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33,462
Closed -$1.97M – 1968
2023
Q4 		$1.97M Buy
33,462
+2,557
+8% +$144K 0.01% 855
2023
Q3 		$1.35M Buy
30,905
+3,202
+12% +$114K 0.01% 969
2023
Q2 		$1M Buy
27,703
+265
+1% +$10.9K 0.01% 1157
2023
Q1 		$1.02M Sell
27,438
-17,875
-39% -$804K 0.01% 1174
2022
Q4 		$2.05M Buy
45,313
+20,973
+86% +$1.36M 0.02% 846
2022
Q3 		$1.7M Sell
24,340
-7,570
-24% -$560K 0.02% 903
2022
Q2 		$2.14M Buy
31,910
+4,110
+15% +$261K 0.02% 867
2022
Q1 		$2.29M Buy
27,800
+3,468
+14% +$355K 0.01% 949
2021
Q4 		$3.57M Buy
24,332
+3,437
+16% +$534K 0.02% 819
2021
Q3 		$3.7M Sell
20,895
-693
-3% -$111K 0.02% 786
2021
Q2 		$3.49M Buy
21,588
+552
+3% +$88.6K 0.02% 817
2021
Q1 		$3.6M Buy
21,036
+2,795
+15% +$553K 0.02% 764
2020
Q4 		$4.01M Sell
18,241
-2,981
-14% -$644K 0.03% 682
2020
Q3 		$3.52M Sell
21,222
-10,656
-33% -$1.46M 0.03% 667
2020
Q2 		$3.64M Buy
31,878
+6,941
+28% +$673K 0.03% 645
2020
Q1 		$1.92M Sell
24,937
-7,379
-23% -$662K 0.02% 805
2019
Q4 		$4.16M Buy
+32,316
New +$3.12M 0.03% 714
2019
Q3 		– Sell
-2,560
Closed -$263K – 2162
2019
Q2 		$263K Buy
+2,560
New +$199K ﹤0.01% 1923

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Guggenheim Capital's MRTX Position: Q1 2024 in Review

Guggenheim Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 33,462 shares — an estimated $1.97M sold.

Guggenheim Capital first reported a position in MRTX in Q2 2019 and held it in 18 quarters. The position peaked at $4.16M in Q4 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Guggenheim Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Guggenheim Capital sold 33,462 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.97M.
  • Guggenheim Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
  • Guggenheim Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $4.16M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Guggenheim Capital's 13F filing for Q1 2024, filed 14 May 2024.